ADMA Biologics Announces First Commercial Sales of ASCENIV™
see the press release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook:READ MOREADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions:READ MOREADMA Biologics Added to NASDAQ Biotechnology Index
ADMA Biologics Added to NASDAQ Biotechnology Index:READ MORE